150
Participants
Start Date
January 23, 2024
Primary Completion Date
May 2, 2030
Study Completion Date
May 2, 2030
BMS-986453
Specified dose on specified days
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Clinica Universidad de Navarra, Pamplona
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca
NOT_YET_RECRUITING
Local Institution - 0008, Nashville
RECRUITING
Tennessee Oncology, Nashville
RECRUITING
Universitaetsklinikum Koeln, Cologne
RECRUITING
Hôpital Saint-Louis, Paris
RECRUITING
Colorado Blood Cancer Institute, Denver
RECRUITING
City of Hope Comprehensive Cancer Center, Duarte
RECRUITING
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
RECRUITING
Stanford University Medical Center, Stanford
RECRUITING
Universitaetsklinikum Wuerzburg, Würzburg
RECRUITING
Swedish Medical Center, Seattle
RECRUITING
Yale Cancer Center, New Haven
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
Universitaetsklinikum Heidelberg, Heidelberg
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
INDUSTRY